Abstract Library

#4648 Analysis of presentation and outcomes of mixed adenoneuroendocrine carcinoma (MANEC) – A single centre experience

Introduction: Mixed adenoneuroendocrine carcinoma (MANEC) is a rare neoplasm characterised by the coexistence of both adenocarcinoma and neuroendocrine carcinoma components. Due to its rarity, limited data exist regarding its clinical presentation, treatment strategies, and outcomes. This study provides an analysis of MANEC cases from a single centre, providing insights into its clinical features, diagnostic challenges, treatment strategies, and prognosis.

Conference:

Presenting Author: Khosla D

Authors: Khosla D, Kapoor R, Mehta A, Gupta R, Singh H,

Keywords: MANEC, mixed adenoneuroendocrine carcinoma, treatment,

#4587 Exploring the splicing landscape to identify survival-related biomarkers in small intestine neuroendocrine neoplasms

Introduction: The study of small intestine neuroendocrine neoplasms (siNENs) is challenging due to their rarity and complexity. While transcriptomic subtypes have been identified, the mechanisms behind their progression are still unclear. The process of RNA splicing is often altered in cancer, and our group has described that such dysregulation is also present in various NENs.

Conference:

Presenting Author: Ibáñez Costa A

Authors: Ibáñez-Costa A, García Vioque V, Pedraza-Arévalo S, Hernando Cubero J, García A,

Keywords: small intestine neuroendocrine tumour, splicing, biomarker, survival, ki-67, RNA,

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,

#4284 Malignant GEP-NET with CBD stricture and portal lymphadenopathy – A rare case report and review of literature

Introduction: Gastric neuroendocrine tumours (gNET) are neoplasms derived from enterochromaffin-like cells (ECL cells). A malignant gastrointestinal neuroectodermal tumour (GNET) is an extremely rare tumour with only less than 40 reported cases. They are rare lesions with indolent behaviour and neuroendocrine differentiation.

Conference:

Presenting Author: Farman A

Authors: Farman A, Raghavendra B, Subash K,

Keywords: carcinoid, gNET, GEP-NET, portal, CBD stricture, gastrectomy, lymphadenopathy,

#4225 Digestive neuroendocrine tumors – Retrospective study and experience of the general surgery department of EHU Oran

Introduction: Neuroendocrine tumors are rare tumors and represent 1% of all digestive tumors, their incidence has seen a constant increase in recent decades, possibly linked to better diagnostic methods and better knowledge of these tumors. Surgery remains the only curative treatment for localized endocrine tumors. The rarity and heterogeneity of these tumors makes their management difficult and explains the low number of randomized studies and the associated low level of evidence.

Conference:

Presenting Author:

Authors: Bennaoum S, Kaid M,

Keywords: surgery, neuroendcrine digestive tumor,